Scinovia offering is now closed and is no longer accepting investments.
INVEST IN SCINOVIA TODAY!
Point-and-Image to Know-the-Flow
$112,512.53 Raised
REASONS TO INVEST
Help save more lives with an FDA Class I Augmented Reality Surgical Camera
300 million surgeries per year and good blood flow is a key to recovery
Current measurement tools originated in the ‘60s and require contact or injection of a contrast dye.
$500M market | probe | dye | 300M per year
OVERVIEW
MedTech imaging for non-contact visualization of blood flow
Scinovia Corp. is a medtech company engaged in the development of proprietary, non-contact diagnostics for cardiovascular and vascular surgeries with the aim to enhance patient outcomes, making surgeries safer and more cost-effective. We focus on improving outcomes of heart bypass, revascularization, and organ transplant therapies where blood flow is key to recovery and to reduce death and costly complications.
Scinovia is entering a growing market of $500M in sales last year with a revolutionary device VUFLOW that provides non-contact, real-time, quantitative data. Presently, the market relies on contact methods that were developed 60 years ago.
Our product roadmap includes a robotic-assisted diagnostic to enhance ease of use and precision while visualizing blood flow during surgery.
Scinovia is a pre-revenue, FDA registered company. VUFLOW units are being scheduled to enter hospitals in 2022 to explore diverse therapeutic areas and generate revenue
Product Use Video:
THE PROBLEM
Assessing the blood flow for surgery is challenging and costly
1. A top challenge surgeons face is knowing whether a procedure has poor blood flow.The number one problem surgeons face is knowing whether a procedure has poor blood flow. 20% of bypass grafts have less than 50% of average blood flow and 14% of breast reconstruction have necrosis. These cases add up: it costs around $100k per case to address breast tissue necrosis.
2. Current tools require contact and have challenges.
THE SOLUTION
Know-the-flow in real-time with VU-FLOW
Case studies have shown visualizing blood flow during surgeries can substantially assist in predicting if poor outcomes may occur. Poor outcomes result in longer recovery for people, costly complications, re-admissions, re-operations, or death.We designed VUFLOW to be the first non-contact visualization tool. Surgeons can now point-n-image to visualize blood flow.
*Computer generated animation for optional robotic upgrade in 2022
Business Model
Software as a Service will be offered on a pay-per-case basis and a multi-year subscription will be offered at a discount, which can be used to help capitalize sales growth. The data acquisition hardware will undergo periodic upgrades to keep up with new visualization features.
The cost for the first 7 units have been paid. We plan to fund operations through raising capital, selling subscriptions, and leveraging credit facilities through financial services in the MedTech industry.
*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.
We plan to grow based on net income, use credit facilities to cover costs over the 4 month gap from building units to selling subscriptions.
First 2 rows indicate capability to assess blood flow speeds. The last 3 rows indicate safety elements.
THE MARKET
300 million major surgeries are being performed annually
Doctors use contact devices to measure blood flow speeds in over 300,000 cases per year. However, an average of 300 million major procedures are performed annually. The global market is estimated to be over $500M in annual sales.
A market comp Novadaq sold fluorescent angiography devices and was acquired by Stryker for $701M, 7 years after its market cap was approximately $100M on NASDAQ.
*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.
OUR TRACTION
Scheduling clinical studies
Scinovia is an FDA registered manufacturer. Several VU-FLOW units are being scheduled for comparative clinical studies in early 2022. This represents an opportunity for VUFLOW to be published, become known among the societies and conferences, and to assess various indications for potential regulatory clearance.
Surgeons from diverse therapies, e.g., bypass, vascular, plastics, cancer, and emergency rooms have shown strong interest in exploring ways that VUFLOW could help in various procedures.
*The above images include a rendering of a future product. Product is still currently under development not yet available on the market.
Scinovia is currently integrating a robotic assisted option that will auto-adjust imaging to reduce glare and improve precision and ease-of-use.
*The above is a rendering of a future product. Product is still currently under development not yet available on the market.
WHY INVEST
Join a game-changing company
We aim to innovate and provide doctors with better tools to improve outcomes for loved ones. We’re targeting existing users of contact devices to switch to our revolutionary non-contact VUFLOW. Last year, hospitals spent over $500M on contact devices.
Our goal is for VUFLOW, which is a platform technology, to become an appliance that is used across many types of procedures.
*The above is a rendering of a future product. Product is still currently under development not yet available on the market.
ABOUT
HEADQUARTERS
8801 Fast Park Dr, STE 301
Raleigh, NC 27617
VALUATION
$89.29M
Scinovia’s mission is to produce state-of-the-art diagnostics to help doctors make more data-driven decisions during procedures to save more lives. Scinovia developed VUFLOW, the future of non-contact imaging diagnostics for blood flow during surgery.
TEAM
Jim Sund, PhD, MBA
CEO and Founder
PhD - Electrical & Computer Engineering, Duke University
MBA - Duke University
BS - Chemistry, University of Florida.
BS - Biology, University of Florida
Dr. Randall Wolf
Surgeon Advisor
* first heart bypass using DaVinci robot
* Professor & Heart Surgeon, Houston Methodist
* Inventor of Wolf Mini Maze for A-fib
* Master Magician
Randall K. Wolf, M.D., is a leading innovator in minimally invasive treatment of atrial fibrillation. The first North American heart surgeon to perform robotic assisted coronary bypass, Dr. Wolf has pioneered DaVinci cardiac surgery and a number of other cardiothoracic procedures including the Wolf Minimaze, endoscopic first rib resection and endoscopic thoracic spine surgery.
Dr. Wolf has authored over 100 peer reviewed articles and book chapters. He has served as president of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) and president of the 21st Century Cardiothoracic Surgery Society. He has also served as Professor of Surgery at Ohio State University; Professor of Surgery and Biomedical Engineering at the University of Cincinnati; and Visiting Professor at The University of Texas.
BA - Indiana University
MD - Indiana University School of Medicine
Jeff Haag
VP of Engineering
He brings a very complete background of software systems with deep expertise in Device Management, Real-Time processing, Networking, Security, and Virtualization, wide general knowledge of mechanical and electrical engineering, as well as extensive experience managing technical customer relationships.
MS Computer Science, North Carolina State University
BS Electrical Engineering, Virginia Tech
Dr. Kim Steinmann
Medical Advisor
* Pediatric Emergency Medicine
Kim is board certified in both Pediatric Emergency Medicine and Pediatric Hematology/Oncology. She received her M.D. from the St. Louis University School of Medicine and completed her Pediatric ER residency training at Cardinal Glennon Children’s Hospital in St. Louis. She then completed her Pediatric Hematology/Oncology fellowship at University of Michigan in Ann Arbor, Michigan.
She brings extensive academic, teaching, and clinical experience from her 10+ years as a faculty/staff member at several institutions as well as 10+ years of industry experience, working on both solid and hematological malignancies with early to late phase clinical development of targeted therapies.
Kim is a board member of the pediatric collaborative team. She has had publications in several peer reviewed journals and has presented scientific data at various national and international conferences and training events in oncology and emergency medicine.
M.D., FCCP, FASCO
TERMS
Scinovia
Overview
PRICE PER SHARE
$2.85
DEADLINE
Jun 30, 2022
VALUATION
$89.29M
AMOUNT RAISED
$112,512.53
Breakdown
MIN INVESTMENT
$228.00
MAX INVESTMENT
$106,997.55
MIN NUMBER OF SHARES OFFERED
3,507
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Class C Nonvoting Common Stock
MAX NUMBER OF SHARES OFFERED
375,438
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Scinovia Corp. |
Corporate Address | : | 8801 Fast Park Dr, STE 301, Raleigh, NC 27617 |
Offering Minimum | : | $9,997.80 |
Offering Maximum | : | $1,069,998.30 |
Minimum Investment Amount(per investor) | : | $498.75 |
Terms
Offering Type | : | Equity |
Security Name | : | Class C Nonvoting Common Stock |
Minimum Number of Shares Offered | : | 3,508 |
Maximum Number of Shares Offered | : | 375,438 |
Price per Share | : | $2.85 |
Pre-Money Valuation | : | $89,293,381.35 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Time-Based:
Friends & Family Early Birds Bonus:
Invest within the first 72 hours and receive 20% bonus shares
Super Early Bird Bonus
Invest within the next 72 hours and receive 15% bonus shares
Early Bird Bonus
Invest within the next 7 days and receive 12% bonus shares
Amount-Based:
Invest $1,500+: Receive 15% bonus shares
Invest $5,000+: Receive 20% bonus shares
Invest $25,000+: Receive 25% bonus shares
Invest $50,000+: Receive 30% bonus shares
Invest $100,000+: Receive 40% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Scinovia Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class C Nonvoting Common Stock at $2.85 / share, you will receive 110 shares of Class C Nonvoting Common Stock, meaning you'll own 110 shares for $285. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”. Vendor payments.
PRESS
ALL UPDATES
06.29.22
Last Day to Invest Through StartEngine!
06.29.22
1 Day Left to Invest in Scinovia's StartEngine Campaign!
06.28.22
1 Day Left to Invest in Scinovia on StartEngine!
06.27.22
Scinovia's StartEngine Campaign Closes in 2 Days!
06.25.22
Scinovia's StartEngine Campaign Closes In 4 Days!
06.24.22
Scinovia's StartEngine Campaign Closes In 5 Days!
06.23.22
Scinovia's StartEngine Campaign Closes In 6 Days!
Become a part of advancing the future of surgical technology and invest in Scinovia today
With only six more days left of our StartEngine Campaign, we hope you'll consider joining us on this journey!
06.22.22
Scinovia's SE Campaign Closing In a Week!
REWARDS
$498.00
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,500.00
$1,500+ Tier
Invest $1,500+ and receive 15% bonus shares
$5,000.00
$5,000+ Tier
Invest $5,000+ and receive 20% bonus shares
$25,000.00
$25,000+ Tier
Invest $25,000+ and receive 25% bonus shares
$50,000.00
$50,000+ Tier
Invest $50,000+ and receive 30% bonus shares
$100,000.00
$100,000+ Tier
Invest $100,000+ and receive 40% bonus shares
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
